What is the current stock price of Crinetics Pharmaceuticals, Inc. (CRNX)?

As of the latest market data, Crinetics Pharmaceuticals, Inc. (CRNX) is trading at $39.44. The stock has seen a loss of -0.48% today.

Does Crinetics Pharmaceuticals, Inc. (CRNX) pay a dividend?

Based on current data, Crinetics Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Crinetics Pharmaceuticals, Inc.?

The current market capitalization of Crinetics Pharmaceuticals, Inc. (CRNX) is approximately unavailable.

CRNX

Crinetics Pharmaceuticals, Inc.·Healthcare

39.44

0.479%(−0.19)

Market Closed

42.00

6.491%(+2.56)

After Hours

Last Updated: — ET

52W L: $25.8352W H: $57.99

CRNX NEWS

globenewswire.com

2d ago

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

defenseworld.net

Mar 29

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation

fool.com

Mar 27

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More

A director of Crinetics Pharmaceuticals reported that he sold 5,000 shares of the company for a transaction value of approximately $180,761 on March 12, 2026. The sale represented 23.47% of Coelho's direct common stock holdings, reducing direct ownership from 21,300 to 16,300 shares.

globenewswire.com

Mar 26

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults. “The submission of our MAA for Palsonify in Brazil represents another important global milestone for this important therapy,” said Scott Struthers, Ph.D.

defenseworld.net

Mar 10

Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf.

Executives from Crinetics Pharmaceuticals (NASDAQ: CRNX) used an investor discussion at TD Cowen's 46th Annual Healthcare Conference to highlight early U.S. commercial progress for its newly launched acromegaly drug, outline upcoming regulatory and clinical milestones, and describe how its pipeline is built around novel small-molecule therapies targeting G protein-coupled receptors (GPCRs). PALSONIFY launch: early demand, reimbursement

defenseworld.net

Mar 9

Intech Investment Management LLC Has $926,000 Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX

Intech Investment Management LLC lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) by 47.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,225 shares of the company's stock after selling 20,408 shares during the quarter. Intech Investment Management LLC's

Company Profile

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Employees

437

IPO Date

2018-07-18

Beta

0.31

Websitewww.crinetics.com↗